Darolutamide APIs from Loncom Pharma are advancing the treatment of prostate cancer by offering a novel androgen receptor antagonist that significantly reduces the risk of metastasis while maintaining a favorable safety profile.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
